company background image
TRX logo

Tissue Regenix Group AIM:TRX Stock Report

Last Price

UK£0.57

Market Cap

UK£40.6m

7D

-1.7%

1Y

1.8%

Updated

11 Dec, 2024

Data

Company Financials +

Tissue Regenix Group plc

AIM:TRX Stock Report

Market Cap: UK£40.6m

TRX Stock Overview

A medical technology company, develops and commercializes platform technologies in the field of bone graft substitutes and soft tissue in the United States and internationally. More details

TRX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Tissue Regenix Group plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Tissue Regenix Group
Historical stock prices
Current Share PriceUK£0.57
52 Week HighUK£0.75
52 Week LowUK£0.50
Beta1.63
11 Month Change-8.06%
3 Month Change-6.56%
1 Year Change1.79%
33 Year Change15.15%
5 Year Change-41.54%
Change since IPO-93.49%

Recent News & Updates

Does Tissue Regenix Group (LON:TRX) Have A Healthy Balance Sheet?

Nov 02
Does Tissue Regenix Group (LON:TRX) Have A Healthy Balance Sheet?

Tissue Regenix Group plc's (LON:TRX) Share Price Is Matching Sentiment Around Its Revenues

Jun 01
Tissue Regenix Group plc's (LON:TRX) Share Price Is Matching Sentiment Around Its Revenues

Recent updates

Does Tissue Regenix Group (LON:TRX) Have A Healthy Balance Sheet?

Nov 02
Does Tissue Regenix Group (LON:TRX) Have A Healthy Balance Sheet?

Tissue Regenix Group plc's (LON:TRX) Share Price Is Matching Sentiment Around Its Revenues

Jun 01
Tissue Regenix Group plc's (LON:TRX) Share Price Is Matching Sentiment Around Its Revenues

Tissue Regenix Group plc's (LON:TRX) Shares Bounce 25% But Its Business Still Trails The Industry

Feb 25
Tissue Regenix Group plc's (LON:TRX) Shares Bounce 25% But Its Business Still Trails The Industry

Is Tissue Regenix Group (LON:TRX) A Risky Investment?

Jun 10
Is Tissue Regenix Group (LON:TRX) A Risky Investment?

Tissue Regenix Group plc (LON:TRX): Are Analysts Optimistic?

Apr 02
Tissue Regenix Group plc (LON:TRX): Are Analysts Optimistic?

Tissue Regenix Group plc (LON:TRX): Are Analysts Optimistic?

Nov 18
Tissue Regenix Group plc (LON:TRX): Are Analysts Optimistic?

Shareholder Returns

TRXGB BiotechsGB Market
7D-1.7%-2.6%-0.6%
1Y1.8%-18.4%7.8%

Return vs Industry: TRX exceeded the UK Biotechs industry which returned -18.4% over the past year.

Return vs Market: TRX underperformed the UK Market which returned 7.8% over the past year.

Price Volatility

Is TRX's price volatile compared to industry and market?
TRX volatility
TRX Average Weekly Movement3.2%
Biotechs Industry Average Movement8.0%
Market Average Movement4.9%
10% most volatile stocks in GB Market10.4%
10% least volatile stocks in GB Market2.6%

Stable Share Price: TRX has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: TRX's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200682Danny Leewww.tissueregenix.com

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of bone graft substitutes and soft tissue in the United States and internationally. The company operates through dCELL, BioRinse, and GBM-V segments. It also provides dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductivity to stimulate and regenerate native bone growth.

Tissue Regenix Group plc Fundamentals Summary

How do Tissue Regenix Group's earnings and revenue compare to its market cap?
TRX fundamental statistics
Market capUK£40.60m
Earnings (TTM)-UK£862.73k
Revenue (TTM)UK£24.92m

1.6x

P/S Ratio

-47.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TRX income statement (TTM)
RevenueUS$31.80m
Cost of RevenueUS$16.06m
Gross ProfitUS$15.73m
Other ExpensesUS$16.84m
Earnings-US$1.10m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.015
Gross Margin49.48%
Net Profit Margin-3.46%
Debt/Equity Ratio34.9%

How did TRX perform over the long term?

See historical performance and comparison